Non-hormonal contraceptive antibodies for on-demand vaginal tablet and monthly ring options
Official title: HMCA-CDRC: Administrative Core
Funded at Mucommune, LLC · NIH-11464358 · Data updated 2026-11-12
A patient-friendly opportunity to support development of a non-hormonal birth control method using a vaginal tablet or ring powered by a potent antibody.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | September 7, 2026 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $82,731 |
| NIH project number | 1P50HD123737-01 |
| Project ID | NIH-11464358 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals seeking non-hormonal contraception who might participate in future HMCA clinical studies and related development activities.
✕Less likely to help
Current participants would not directly benefit until later-stage trials are conducted and approved.
What this research studies
This grant supports Mucommune’s Administrative Core to lead the development of highly multivalent contraceptive antibodies (HMCA) that stop sperm from fertilizing an egg. The work coordinates scientific leadership, regulatory steps, and budgeting to move two HMCA-based products through early human studies and preclinical work. Participants could benefit if future trials test the safety and effectiveness of an on-demand vaginal tablet (MM011) or a month-long vaginal ring (MM012). The program emphasizes collaboration with clinical sites and partners to advance toward real-use contraception, with attention to regulatory and operational needs.
Why it matters
Potential benefit: If successful, this effort could accelerate a non-hormonal contraceptive option that provides on-demand or monthly protection without hormones.
How similar studies have gone: Prior projects have shown progress in translating contraceptive antibodies into clinical development, making this a plausible next step.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Kushiro, Keiichiro — Mucommune, LLC
- Study coordinator: Kushiro, Keiichiro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.